{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:52:22Z","timestamp":1791921142738,"version":"4.3.4"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM201612024"],"award-info":[{"award-number":["SZSM201612024"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202311022"],"award-info":[{"award-number":["SZSM202311022"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202211017"],"award-info":[{"award-number":["SZSM202211017"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022411","name":"The University of Hong Kong-Shenzhen Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016804","name":"Natural Science Foundation of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20220530142413031"],"award-info":[{"award-number":["JCYJ20220530142413031"]}],"id":[{"id":"10.13039\/100016804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016804","name":"Natural Science Foundation of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20250604180831041"],"award-info":[{"award-number":["JCYJ20250604180831041"]}],"id":[{"id":"10.13039\/100016804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ctrv.2026.103214","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:40Z","timestamp":1790348620000},"page":"103214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review"],"prefix":"10.1016","volume":"151","author":[{"given":"Weijie","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Ho Fun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0005","article-title":"The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx","volume":"46","author":"Y","year":"2005","journal-title":"J Nucl Med"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103214_bb0010","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","article-title":"Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging","volume":"31","author":"Tang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0015","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2004.07.702","article-title":"Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience","volume":"61","author":"Lee","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103214_bb0020","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0030","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103214_bb0035","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103214_bb0040","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0045","article-title":"Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study","volume":"11","author":"Huang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"issue":"10054","key":"10.1016\/j.ctrv.2026.103214_bb0050","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103214_bb0055","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103214_bb0060","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00405-021-07192-8","article-title":"Taxane\/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis","volume":"279","author":"Du","year":"2022","journal-title":"Eur Arch Otorrinolaringol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103214_bb0065","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1368-8375(01)00134-8","article-title":"A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"38","author":"McCarthy","year":"2002","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.oraloncology.2005.01.008","article-title":"A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma","volume":"41","author":"Chua","year":"2005","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.107087","article-title":"Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a single center prospective phase II clinical trial","volume":"159","author":"Shang","year":"2024","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hed.26899","article-title":"Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy","volume":"44","author":"Yang","year":"2022","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/cco-23-32","article-title":"Treatment strategy for de novo metastatic nasopharyngeal carcinoma: a literature review","volume":"12","author":"Liu","year":"2023","journal-title":"Chin Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103214_bb0090","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bulcan.2016.11.008","article-title":"Reappraisal role of locoregional radiation therapy in metastatic cancers","volume":"104","author":"Rancoule","year":"2017","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103214_bb0105","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1007\/s00432-022-04341-2","article-title":"Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study","volume":"149","author":"Lu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103214_bb0115","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103214_bb0120","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103214_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103214_bb0130","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","article-title":"Phase II, randomized study of Spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer","volume":"27","author":"Even","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0135","article-title":"Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103214_bb0140","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1200\/JCO.2024.42.16_suppl.6039","article-title":"Four-year overall survival follow-up and dynamic EBV titer analysis of Toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r\/m NPC)","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2026.0020","article-title":"First-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer: three-year follow-up of the phase 3 RATIONALE-309 randomized clinical trial","volume":"12","author":"Yang","year":"2026","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jamaoncol.2025.6245","article-title":"Five-year outcome of camrelizumab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a secondary analysis of the CAPTAIN-1st randomized clinical trial","volume":"12","author":"Huang","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1485609","article-title":"Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis","volume":"16","author":"Cai","year":"2025","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103214_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf188","article-title":"Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma","volume":"30","author":"Li","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105295","article-title":"The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study","volume":"10","author":"He","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103214_bb0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/13543784.2024.2401910","article-title":"Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma","volume":"33","author":"Yan","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103214_bb0175","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s11864-023-01101-3","article-title":"Recurrent\/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading?","volume":"24","author":"Juarez-Vignon Whaley","year":"2023","journal-title":"Curr Treat Options in Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2017.03.030","article-title":"Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - how far have we achieved?","volume":"114","author":"Lee","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0185","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/annonc\/mdq425","article-title":"Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma","volume":"22","author":"Ngeow","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0190","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.2147\/DDDT.S95946","article-title":"Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma","volume":"9","author":"Peng","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103214_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.oraloncology.2014.04.007","article-title":"Single-arm, multi-Centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients","volume":"50","author":"Long","year":"2014","journal-title":"Oral Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103214_bb0200","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.ejca.2012.06.009","article-title":"A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)","volume":"48","author":"Ji","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103214_bb0205","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.oraloncology.2012.05.021","article-title":"Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy","volume":"48","author":"Chen","year":"2012","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cncr.20802","article-title":"Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma","volume":"103","author":"Poon","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00280-012-1950-7","article-title":"Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy","volume":"70","author":"Zhang","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103214_bb0220","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006518","article-title":"Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103214_bb0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105222","article-title":"Efficacy and safety of apatinib in recurrent\/metastatic nasopharyngeal carcinoma: a pilot study","volume":"115","author":"Huang","year":"2021","journal-title":"Oral Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103214_bb0235","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.33626","article-title":"Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: a multicenter, single-arm, prospective phase 2 study","volume":"127","author":"Ruan","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0240","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03140-x","article-title":"Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial","volume":"21","author":"Fang","year":"2023","journal-title":"BMC Med"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103214_bb0245","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","article-title":"A phase II study of pazopanib in Asian patients with recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lim","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103214_bb0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(24)00677-6","article-title":"Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial","volume":"26","author":"Chong","year":"2025","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103214_bb0255","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.22.01450","article-title":"Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study","volume":"41","author":"Ding","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40402-x","article-title":"Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"14","author":"Yuan","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103214_bb0265","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.medj.2022.07.009","article-title":"Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma","volume":"3","author":"You","year":"2022","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028507","article-title":"Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"101","author":"Hong","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0275","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00280-007-0575-8","article-title":"A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy","volume":"62","author":"Ma","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0280","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/annonc\/mdz020","article-title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0285","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","article-title":"Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial","volume":"23","author":"Zou","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.ctrv.2026.103214_bb0290","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.2147\/DDDT.S215190","article-title":"Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study","volume":"13","author":"Sun","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ctrv.2026.103214_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.06.003","article-title":"Becotatug vedotin for recurrent\/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial","author":"Han","year":"2026","journal-title":"Ann Oncol"},{"issue":"10516","key":"10.1016\/j.ctrv.2026.103214_bb0300","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103214_bb0305","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CMAR.S460716","article-title":"Efficacy and safety of re-challenging PD-1 inhibitors in second-line treatment in metastatic nasopharyngeal carcinoma previously treated with chemotherapy and PD-1 inhibitors","volume":"16","author":"Bei","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2026.103214_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104113","article-title":"Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients","volume":"190","author":"Jiang","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106981","article-title":"Gemcitabine, capecitabine, and tislelizumab in recurrent\/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: a retrospective study","volume":"158","author":"Yang","year":"2024","journal-title":"Oral Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103214_bb0320","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1158\/1078-0432.CCR-25-0085","article-title":"GFH018 and Toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: results from a phase Ib\/II study","volume":"31","author":"Tang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103214_bb0325","article-title":"Anti-LAG-3 antibody LBL-007 plus tislelizumab and chemotherapy as first-line therapy for advanced nasopharyngeal carcinoma: a multicenter phase 2 trial","author":"Sun","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103214_bb0330","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.annonc.2024.08.2344","article-title":"Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial","volume":"35","author":"Toh","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103214_bb0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0340","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Nafiseh","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2026.103214_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1536428","article-title":"Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironment","volume":"16","author":"Nemati","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103214_bb0350","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Zehua","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0355","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.resinv.2023.04.009","article-title":"Drastic response to rechallenge with calboplatin plus nab-paclitaxel after immunotherapy in a patient with advanced thymic carcinoma","volume":"61","author":"Fujita","year":"2023","journal-title":"Respir Investig"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103214_bb0360","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.7150\/thno.95619","article-title":"Metronomic chemotherapy in cancer treatment: new wine in an old bottle","volume":"14","author":"Wu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ctrv.2026.103214_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0375","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","article-title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103214_bb0380","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ijc.35340","article-title":"Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm clinical trial","volume":"156","author":"Xiao","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103214_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077890","article-title":"Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial","volume":"385","author":"Liu","year":"2024","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0390","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jamaoncol.2021.7366","volume":"8","author":"Liu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1208475","article-title":"Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma","volume":"14","author":"Secondino","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100313","article-title":"Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial","volume":"6","author":"Zhou","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0405","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3727\/096504014X13983417587401","article-title":"A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)","volume":"21","author":"Jin","year":"2013","journal-title":"Oncol Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0410","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/annonc\/mds581","article-title":"Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma","volume":"24","author":"Xue","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103214_bb0415","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jjco\/hyv083","article-title":"Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective phase II trial","volume":"45","author":"Hsieh","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-007-0641-2","article-title":"Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma","volume":"62","author":"Li","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103214_bb0425","first-page":"229","article-title":"Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"36","author":"Hsieh","year":"2013","journal-title":"Biom J"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103214_bb0430","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.23687","article-title":"Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma","volume":"113","author":"Leong","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103214_bb0435","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.20804","article-title":"Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination","volume":"103","author":"Leong","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103214_bb0440","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","article-title":"Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study","volume":"13","author":"Ngan","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103214_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101029","article-title":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase IIa trial","volume":"7","author":"Han","year":"2026","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103214_bb0450","article-title":"Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm phase 2 trial (TORAL)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0455","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-03985-4","article-title":"Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial","volume":"23","author":"Jiang","year":"2025","journal-title":"BMC Med"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103214_bb0460","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-22-1238","article-title":"A phase II study of nivolumab plus gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma (KCSG HN17\u201311)","volume":"28","author":"Jung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103214_bb0465","article-title":"Apatinib combined with camrelizumab in the treatment of recurrent\/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study","volume":"14","author":"Mo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103214_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102136","article-title":"Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study","volume":"62","author":"Lu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2026.103214_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): a phase II multicenter study","volume":"151","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-02790-1","article-title":"The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and\/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial","volume":"21","author":"Tang","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103214_bb0485","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103214_bb0490","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2019.10.002","article-title":"Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma","volume":"123","author":"Mesia","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103214_bb0495","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00280-013-2203-0","article-title":"Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy","volume":"72","author":"Peng","year":"2013","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:39:50Z","timestamp":1791920390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":99,"alternative-id":["S0305737226001283"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103214","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103214"}}